Research Activity
Cartesian Therapeutics Announces Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis Treatment
Cartesian Therapeutics, Descartes-08, Myasthenia Gravis, Phase 2b Trial, CAR-T Therapy, Autoimmune Disorder
Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment
Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
TRACON Pharmaceuticals Discontinues Envafolimab Development, Explores Strategic Options
TRACON Pharmaceuticals, Envafolimab, Oncology, Clinical Trial, Strategic Options, Mergers, Acquisitions, Asset Sales
Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment
Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval
FDA Publishes Updated Draft Guidance on Clinical Trial Diversity
FDA, Clinical Trials, Diversity, Inclusion, Medical Products, Racial and Ethnic Representation
J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial
Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission
EvolutionaryScale Secures $142M for AI-Driven Drug Discovery
EvolutionaryScale, AI-driven drug discovery, $142M investment, drug development, pharmaceuticals
AstraZeneca’s Imfinzi Achieves Success in Bladder Cancer Trial, Falls Short in Lung Cancer Study
AstraZeneca, Imfinzi, bladder cancer, lung cancer, Phase III trials, disease-free survival
Merck KGaA Discontinues Xevinapant Program in Locally Advanced Head and Neck Cancer Due to Phase III Trial Failure
Merck KGaA, xevinapant, Phase III trial, head and neck cancer, TrilynX study, X-Ray Vision study, oncology pipeline, apoptosis proteins inhibitor
Merck KGaA Discontinues Xevinapant Program for Locally Advanced Head and Neck Cancer
Merck KGaA, Xevinapant, Head and Neck Cancer, Phase III Trial, Discontinuation, Cancer Treatment